1. Home
  2. CYTK vs LBTYA Comparison

CYTK vs LBTYA Comparison

Compare CYTK & LBTYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • LBTYA
  • Stock Information
  • Founded
  • CYTK 1997
  • LBTYA 2004
  • Country
  • CYTK United States
  • LBTYA Bermuda
  • Employees
  • CYTK N/A
  • LBTYA N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • LBTYA Cable & Other Pay Television Services
  • Sector
  • CYTK Health Care
  • LBTYA Telecommunications
  • Exchange
  • CYTK Nasdaq
  • LBTYA Nasdaq
  • Market Cap
  • CYTK 4.4B
  • LBTYA 3.7B
  • IPO Year
  • CYTK 2004
  • LBTYA N/A
  • Fundamental
  • Price
  • CYTK $38.62
  • LBTYA $11.53
  • Analyst Decision
  • CYTK Buy
  • LBTYA Buy
  • Analyst Count
  • CYTK 13
  • LBTYA 5
  • Target Price
  • CYTK $71.58
  • LBTYA $14.96
  • AVG Volume (30 Days)
  • CYTK 1.4M
  • LBTYA 2.2M
  • Earning Date
  • CYTK 08-07-2025
  • LBTYA 08-01-2025
  • Dividend Yield
  • CYTK N/A
  • LBTYA N/A
  • EPS Growth
  • CYTK N/A
  • LBTYA N/A
  • EPS
  • CYTK N/A
  • LBTYA N/A
  • Revenue
  • CYTK $85,738,000.00
  • LBTYA $4,633,000,000.00
  • Revenue This Year
  • CYTK $27.08
  • LBTYA $8.82
  • Revenue Next Year
  • CYTK $652.09
  • LBTYA $1.16
  • P/E Ratio
  • CYTK N/A
  • LBTYA N/A
  • Revenue Growth
  • CYTK 2635.74
  • LBTYA 81.79
  • 52 Week Low
  • CYTK $29.31
  • LBTYA $9.03
  • 52 Week High
  • CYTK $59.39
  • LBTYA $21.56
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 60.89
  • LBTYA 74.57
  • Support Level
  • CYTK $32.89
  • LBTYA $10.81
  • Resistance Level
  • CYTK $36.79
  • LBTYA $11.14
  • Average True Range (ATR)
  • CYTK 1.73
  • LBTYA 0.35
  • MACD
  • CYTK 0.15
  • LBTYA 0.09
  • Stochastic Oscillator
  • CYTK 91.77
  • LBTYA 98.70

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About LBTYA Liberty Global Ltd.

Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.

Share on Social Networks: